<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607321</url>
  </required_header>
  <id_info>
    <org_study_id>IP088</org_study_id>
    <nct_id>NCT00607321</nct_id>
  </id_info>
  <brief_title>Bare Metal Bifurcation Stent Clinical Trial in Humans</brief_title>
  <acronym>BRANCH</acronym>
  <official_title>The Medtronic Bare Metal Bifurcation Stent Clinical Trial in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the feasibility and safety of the Medtronic Bifurcation Stent System for the
      treatment of single de novo bifurcation lesions in native coronary arteries with reference
      vessel diameters (RVD) for the proximal main vessel of 3.8 - 4.3 mm, distal main branch of
      3.0 - 3.5 mm, and side branch RVD up to 2.5 mm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF) at 30 Days Post Procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>During index procedure</time_frame>
    <description>Device success is reported as Historical-standard definition: attainment of &lt;50% residual stenosis of all target lesion/s using only the assigned device and any adjunct stents as specified in the Investigational Plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF) at 6 Months</measure>
    <time_frame>6 month</time_frame>
    <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure at 9 Months.</measure>
    <time_frame>9 month</time_frame>
    <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Target Vessel Failure at 12 Months</measure>
    <time_frame>12 month</time_frame>
    <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medtronic Bifurcation Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Bifurcation Stent System</intervention_name>
    <description>Percutaneous Coronary Stenting</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria

          -  Candidate for percutaneous coronary intervention &amp; emergent coronary artery bypass
             graft surgery

          -  Clinical evidence of ischemic heart disease or a positive functional study

          -  Female patients of childbearing potential has negative pregnancy test within 7 days
             before trial procedure

          -  Patient or patient's legal representative provided written informed consent

          -  Patient agrees to comply with follow-up evaluations

        Angiographic Inclusion Criteria

          -  Target lesion ia a single de novo bifurcation lesion involving a native coronary
             artery with reference vessel diameter for the proximal main of 3.8 - 4.3 mm, distal
             main of 3.0 - 3.5 mm, &amp; side branch RVD up to 2.5 mm

          -  Acceptable target lesion lengths are any combination of:

          -  &lt;16mm proximally from carina in proximal main vessel

          -  &lt;16mm distally from the carina in distal main branch

          -  &lt;12mm from carina in side branch

          -  Target lesion in main vessel has stenosis of &gt; 50% and &lt;100%

          -  Target vessel has (TIMI) flow &gt;2

        General Exclusion Criteria

          -  Known hypersensitivity/contraindication to aspirin, heparin or bivalirudin,
             clopidogrel or ticlopidine, cobalt, nickel, chromium, molybdenum, or sensitivity to
             contrast media, which can't be adequately pre-medicated

          -  Platelet count &lt;100,000 cells/mm³ or &gt;700,000 cells/mm³, or a white blood cell (WBC)
             count &lt;3,000 cells/mm³ within 7 days prior to index procedure

          -  Serum creatinine level &gt;170 micromol/L within 7 days prior to index procedure

          -  Evidence of acute MI within 72 hours of intended trial procedure (defined as: QWMI or
             NQWMI having CK enzymes &gt;2X laboratory upper limit of normal with presence of elevated
             CK-MB (any amount above laboratory upper limit of normal)

          -  Previous stenting anywhere in target vessel

          -  PCI of non-target vessel within 30 days prior to procedure that results in any MACE
             event. If non target vessel stent is implanted within 72 hours prior to index
             procedure, 2 post procedural serial CK or CK-MB measurements must be below
             investigational site's upper limit of normal.

          -  PCI of non-target vessel within 24 hours prior to procedure

          -  Planned PCI of any vessel within 30 days post-procedure

          -  Planned PCI of the target vessel within 6 months post-procedure

          -  During index procedure, target lesion requires treatment with device other than PTCA
             or cutting balloon prior to stent placement

          -  Documented left ventricular ejection fraction (LVEF) &lt;30% at most recent evaluation.

          -  History of stroke or transient ischemic attack (TIA) within prior 6 months

          -  Active peptic ulcer or upper gastrointestinal (GI) bleeding within prior 6 months

          -  History of bleeding diathesis or coagulopathy or will refuse blood transfusions

          -  Concurrent medical condition with life expectancy &lt; 12 months

          -  Currently participating in investigational drug or device trial that's not completed
             the primary endpoint or that clinically interferes with current trial endpoints; or
             requires coronary angiography, IVUS or other coronary artery imaging procedures.

        Angiographic Exclusion Criteria

          -  Bifurcation angle of &gt;90 degrees by visual estimate

          -  Target lesion located in native vessel with saphenous vein graft or left/right
             internal mammary artery (LIMA/RIMA) bypass

          -  Significant stenosis (&gt;50%) proximal or distal to target lesion that might require
             revascularization or impede run off.

          -  Target vessel is excessively tortuous (two bends &gt;90º to reach target lesion)

          -  Target lesion has any of following characteristics:

          -  Lesion location is aorto-ostial, unprotected left main lesion, or within 5 mm of
             origin of left anterior descending (LAD), left circumflex (LCX), or right coronary
             artery (RCA).

          -  Severely calcified

          -  Evidence of thrombus

          -  Co-existence of unprotected left main coronary artery disease (obstruction &gt;50% in
             left main coronary artery)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Meredith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <results_first_submitted>August 1, 2011</results_first_submitted>
  <results_first_submitted_qc>August 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2011</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>restenosis</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Coronary Arteriosclerosis</keyword>
  <keyword>Arterial Occlusive Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Medtronic Bifurcation Stent System</title>
          <description>Single arm, All patients single de novo bifurcation lesions; 7 run-in subjects not included in analysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Medtronic Bifurcation Stent System</title>
          <description>Single arm, All patients single de novo bifurcation lesions; 7 run-in subjects not included in analysis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Target Vessel Failure (TVF) at 30 Days Post Procedure.</title>
        <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects Receiving Bifurcation Stents</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF) at 30 Days Post Procedure.</title>
          <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>Device success is reported as Historical-standard definition: attainment of &lt;50% residual stenosis of all target lesion/s using only the assigned device and any adjunct stents as specified in the Investigational Plan.</description>
        <time_frame>During index procedure</time_frame>
        <population>ITT included all subjects after a run-in subject at each site.</population>
        <group_list>
          <group group_id="O1">
            <title>Bifurcation Stent System</title>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>Device success is reported as Historical-standard definition: attainment of &lt;50% residual stenosis of all target lesion/s using only the assigned device and any adjunct stents as specified in the Investigational Plan.</description>
          <population>ITT included all subjects after a run-in subject at each site.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF) at 6 Months</title>
        <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
        <time_frame>6 month</time_frame>
        <population>Includes all patients receiving bifurcation stent and having evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Bifurcation Stent System</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF) at 6 Months</title>
          <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
          <population>Includes all patients receiving bifurcation stent and having evaluable data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure at 9 Months.</title>
        <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
        <time_frame>9 month</time_frame>
        <population>Includes all subjects receiving bifurcation stents and having evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Bifurcation Stent System</title>
            <description>Evaluable patients within pre-specified follow up window</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure at 9 Months.</title>
          <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
          <population>Includes all subjects receiving bifurcation stents and having evaluable data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Target Vessel Failure at 12 Months</title>
        <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
        <time_frame>12 month</time_frame>
        <population>Includes all subjects receiving bifurcation stents and having evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Receiving Bifurcation Stents</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Target Vessel Failure at 12 Months</title>
          <description>TVF was reported if any of the following events occurred: Recurrent MI in territory not clearly attributed to a vessel other than the target lesion; Cardiac death not clearly due to a non-target vessel endpoint or Clinically driven target revascularization.</description>
          <population>Includes all subjects receiving bifurcation stents and having evaluable data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1. Branch Bifurcation Stent System</title>
          <description>All subjects enrolled in the BRANCH study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device Malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain In Jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary Revascularisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Coronary Artery Dissection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>K Bogdanovich</name_or_title>
      <organization>Medtronic Cardiovascular</organization>
      <email>rs.medtroniccardiovascularclinicaltrials@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

